RM-004

N/A

Report date: 2024/12/27 20:00:34

Base Information

Drug NameRM-004
Drug Alias NameRM-004
ClassificationCell and gene therapy > Gene therapy > Gene editing
Mechanisms of ActionGene modulators
TargetsUpdating
Therapy Area/IndicationsGenetic Diseases, InbornHemoglobinopathiesalpha-Thalassemia +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Reforgene Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Reforgene Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsGenetic Diseases, InbornHemoglobinopathiesalpha-Thalassemia +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A